Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

95.61USD
23 Feb 2018
Change (% chg)

$1.83 (+1.95%)
Prev Close
$93.78
Open
$94.54
Day's High
$95.66
Day's Low
$93.94
Volume
4,031,211
Avg. Vol
8,153,147
52-wk High
$147.17
52-wk Low
$88.32

Latest Key Developments (Source: Significant Developments)

Celgene Receives Antitrust Clearance For Juno Acquisition
Wednesday, 21 Feb 2018 07:30am EST 

Feb 21 (Reuters) - Celgene Corp ::CELGENE RECEIVES ANTITRUST CLEARANCE FOR JUNO ACQUISITION.CELGENE CORP - ‍CELGENE EXPECTS JUNO TRANSACTION TO CLOSE IN Q1 OF 2018​.  Full Article

Celgene Says Otezla Phase II Data Showed Clinically Meaningful Improvements In Active Ulcerative Colitis Patients
Thursday, 15 Feb 2018 09:30am EST 

Feb 15 (Reuters) - Celgene Corp ::OTEZLA® (APREMILAST) PHASE II DATA SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS.CELGENE CORP - ‍PHASE III PROGRAM WITH OTEZLA (APREMILAST) IN ULCERATIVE COLITIS EXPECTED TO BEGIN IN 2018​.CELGENE CORP - ‍PRIMARY ENDPOINT OF STUDY WAS TOTAL MAYO SCORE CLINICAL REMISSION AT WEEK 12 FOR 40 MG BID ARM​.  Full Article

Celgene Announces Additional $5 Billion Share Repurchase Authorization
Wednesday, 14 Feb 2018 07:30am EST 

Feb 14 (Reuters) - Celgene Corp ::CELGENE ANNOUNCES ADDITIONAL $5 BILLION SHARE REPURCHASE AUTHORIZATION.CELGENE ANNOUNCES ADDITIONAL $5 BILLION SHARE REPURCHASE AUTHORIZATION.CELGENE CORP - ‍OPEN-ENDED PROGRAM IS EFFECTIVE IMMEDIATELY​.  Full Article

Celgene Prices $4.5 Billion Of Senior Unsecured Notes
Friday, 9 Feb 2018 07:30am EST 

Feb 9 (Reuters) - Celgene Corp ::CELGENE PRICES $4.5 BILLION OF SENIOR UNSECURED NOTES.CELGENE CORP - ANNOUNCED PRICING OF FOUR SERIES OF SENIOR UNSECURED NOTES.CELGENE CORP - NOTES OF $500 MILLION WILL MATURE IN 2021 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 2.875 PERCENT.CELGENE CORP - NOTES OF $1.0 BILLION WILL MATURE IN 2023 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 3.25 PERCENT.CELGENE CORP - NOTES OF $1.5 BILLION WILL MATURE IN 2028 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 3.90 PERCENT.CELGENE CORP - NOTES OF $1.5 BILLION WILL MATURE IN 2048 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 4.55 PERCENT.CELGENE CORP - 2.875 PERCENT NOTES DUE 2021, 3.25 PERCENT NOTES DUE 2023, 3.90 PERCENT NOTES DUE IN 2028 , 4.55 PERCENT NOTES DUE IN 2048.  Full Article

Celgene Announces Offering Of Senior Unsecured Notes
Thursday, 8 Feb 2018 08:55am EST 

Feb 8 (Reuters) - Celgene Corp ::CELGENE ANNOUNCES OFFERING OF SENIOR UNSECURED NOTES.CELGENE CORP - EXPECTS TO USE NET PROCEEDS FROM OFFERING TO FINANCE A PORTION OF ACQUISITION OF JUNO THERAPEUTICS.  Full Article

Celgene Is In Talks To Buy Juno Therapeutics -WSJ Reporter Tweet‍​
Tuesday, 16 Jan 2018 04:49pm EST 

Jan 16 (Reuters) - :CELGENE IS IN TALKS TO BUY JUNO THERAPEUTICS -WSJ REPORTER TWEET‍​.  Full Article

Celgene CEO Says Plans To Invest Heavily In R&D In 2018
Monday, 8 Jan 2018 10:57am EST 

Jan 8 (Reuters) - Celgene Corp ::CELGENE CEO SAYS PLANS TO INVEST HEAVILY IN RESEARCH AND DEVELOPMENT, BUSINESS DEVELOPMENT IN 2018.CELGENE SAYS HAS 10 LATE STAGE MOLECULES WITH BILLION TO MULTIBILLION-DOLLAR POTENTIAL; COULD ADD MORE THAN $15 BILLION PEAK REVENUE.  Full Article

Celgene Says Expects FY 2018 Rev To Be About $14.4 Bln To $14.8 Bln
Monday, 8 Jan 2018 10:35am EST 

Jan 8 (Reuters) - Celgene Corp ::SEES PRELIMINARY Q4 REVLIMID SALES $2,188 MILLION.ORATION ANNOUNCES PRELIMINARY 2017 UNAUDITED RESULTS AND 2018 FINANCIAL GUIDANCE.SEES Q4 2017 ADJUSTED EARNINGS PER SHARE ABOUT $2.00.SEES FY 2017 GAAP EARNINGS PER SHARE $3.64 TO $4.19.SEES Q4 2017 GAAP LOSS PER SHARE $0.09 TO $+0.46.SEES FY 2018 REVENUE UP 12 PERCENT.SEES FY 2018 REVENUE ABOUT $14.4 BILLION TO $14.8 BILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $8.70 TO $8.90.SEES FY 2020 REVENUE $19 BILLION TO $20 BILLION.SEES FY 2017 ADJUSTED EARNINGS PER SHARE ABOUT $7.44.Q4 REVENUE $3.5 BILLION VERSUS I/B/E/S VIEW $3.46 BILLION.SEES PRELIMINARY Q4 OTEZLA SALES $371 MILLION.FY2017 EARNINGS PER SHARE VIEW $7.34, REVENUE VIEW $12.98 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $8.71, REVENUE VIEW $14.83 BILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $1.93, REVENUE VIEW $3.46 BILLION -- THOMSON REUTERS I/B/E/S.REAFFIRMING 2020 TOTAL REVENUE AND ADJUSTED DILUTED EPS FINANCIAL TARGETS.FULL YEAR 2017 GAAP OPERATING MARGIN IS EXPECTED TO BE ABOUT 36 PERCENT.CELGENE - ESTIMATED GAAP EARNINGS PER SHARE FOR QUARTER & YEAR ENDED DEC 31, 2017 INCLUDE ESTIMATED IMPACT OF ABOUT $800 MILLION-ABOUT $1,300 MILLION DUE TO TAX CUTS AND JOBS ACT.‍BASED ON GAAP, EPS FOR FULL-YEAR 2018 IS EXPECTED TO BE IN RANGE OF $6.58 TO $6.95​.  Full Article

Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA
Thursday, 16 Nov 2017 08:30am EST 

Nov 16 (Reuters) - Celgene Corp :Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma.Celgene Corp - ‍designations based on preliminary clinical data from ongoing phase i study of bb2121 in heavily pre-treated multiple myeloma​.Celgene Corp - ‍updated data from CRB-401 is scheduled to be presented at 59(th) annual meeting of american society of hematology in Atlanta​.  Full Article

Celgene prices $3 billion of senior unsecured notes
Wednesday, 1 Nov 2017 07:30am EDT 

Nov 1 (Reuters) - Celgene Corp :Celgene prices $3 billion of senior unsecured notes.Celgene Corp - ‍announced pricing of three series of senior unsecured notes for aggregate principal amount of $3,000 million​.  Full Article

BRIEF-Celgene Receives Antitrust Clearance For Juno Acquisition

* CELGENE CORP - ‍CELGENE EXPECTS JUNO TRANSACTION TO CLOSE IN Q1 OF 2018​ Source text for Eikon: Further company coverage: